class action lawsuit

Plug Power faces class action lawsuit alleging false statements about DOE loans and hydrogen facilities. Investors have until April 3, 2026 to apply as lead plaintiffs.

BlackRock TCP Capital faces class action lawsuit after 19% NAV decline and 12.97% stock plunge. Investors must act by April 6 deadline.

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

Class action lawsuit filed against China Liberal Education Holdings for alleged pump-and-dump scheme coordinating with scammers, resulting in $300M+ investor losses.

Ramaco Resources faces class action lawsuit over alleged false Brook Mine operational claims, with lead plaintiff deadline set for March 31, 2026.

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

BlackRock faces securities fraud investigation after implementing 5% quarterly redemption caps on HPS Corporate Lending Fund, triggering 7.69% stock decline.

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

Pomerantz LLP investigates Freshpet for potential securities fraud tied to unsupported 'human grade' pet food claims, triggering sharp stock decline.

Microvast ($MVST) plunged 34% after reporting $96.5M revenue (29% below consensus) and 1% gross margins, triggering securities fraud investigation by Pomerantz LLP.

Pomerantz Law Firm investigates $CFLT over undisclosed AI customer spending reduction that caused stock to crash 32.86% on July 31, 2025.

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

Goldman Sachs sued as lead underwriter for allegedly failing to disclose 39% surge in Navan's marketing costs before October 2025 IPO, resulting in 63% stock collapse.

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

$LAKE faces class action suit alleging executives misrepresented acquisition integration and hid operational problems, leading to 39% stock crash.

Pomerantz Law Firm files class action against Enphase Energy over alleged misstatements regarding inventory management and federal solar tax credit impacts. Stock fell 15.15% after weak Q3 guidance.

Schall Law Firm seeks $PSIX investors for class action over alleged false statements on data center business and manufacturing costs. Deadline: May 19, 2026.

Navan investors face April 2026 deadline to join class action over allegedly misleading IPO disclosures. Stock has fallen 63% after undisclosed 39% expense increase announcement.

Schall Law Firm launches securities fraud class action against $GEMI, alleging misleading statements about crypto platform and expansion plans since September 2025 IPO.